<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951884</url>
  </required_header>
  <id_info>
    <org_study_id>208755</org_study_id>
    <nct_id>NCT02951884</nct_id>
  </id_info>
  <brief_title>Intra-articular Local Anesthetic Injection and Hematoma Aspiration</brief_title>
  <official_title>The Effect of Intra-articular Local Anesthetic Injection and Hematoma Aspiration on Pain and Narcotic Analgesia Use Following Tibial Plateau Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether a patient with a tibial plateau
      fracture (non-displaced, displaced, or depression type) will have decreased pain and narcotic
      analgesia requirements following an intra-articular injection of local anesthetic and
      aspiration of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to study tibial plateau fractures treated at our institution for which we have
      fracture data, treated with open reduction internal fixation (ORIF) procedures or treated
      non-operatively. Patients will be identified based on the classification of their injury,
      that being tibial plateau fracture; we will seek to sub-classify each patient based on the
      Shatzker classification of tibial plateau fractures and using knee osteoarthritis (OA)
      classification as our prospective study will be based on both tibial plateau fractures as a
      whole and their sub-classification: Lateral tibial plateau fracture without depression (I),
      lateral tibial plateau fracture with depression (II), compression fracture of the lateral
      (IIIA) or central (IIIB) tibial plateau, medial tibial plateau fracture (IV), bicondylar
      tibial plateau fracture (V), and tibial plateau fracture with diaphyseal discontinuity (VI).
      It is important for our prospective study to classify each fracture pattern as they generally
      differ in energy of injury and thus may affect pain management or need for narcotic pain
      medications and also potentially affect functional outcomes.

      Following consent for participation in the study, patients will be blinded to initial
      management of the tibial plateau fracture with either: Aspiration of the joint alone,
      aspiration of the knee joint and injection of 20cc bupivacaine 0.5% with 1:200,000
      epinephrine, or no injection or aspiration therapy for a control arm. Using the block
      randomization list, the patient will be randomized at the time of consent for participation.
      For the sake of consistency, all participating treating physicians (orthopaedic on-call
      residents) will be trained on Sawbones Fully Encased Knee Joint with Patella and Ligaments
      for a standardized aspiration and injection technique.

      For the patients randomized into the treatment arms, the knee will be held in 15-30 degrees
      short of full extension and fully prepped using chlorhexidine wipes in a centrifugal manner.
      An 18 gauge spinal needle will be introduced into the superolateral aspect of the knee (if
      the knee is too edematous, an inferolateral or inferomedial approach may be appropriate). We
      will aspirate the knee with a 60cc syringe until we are unable to draw out more fluid and
      record the volume on a case record form. Subsequently, we will remove the syringe from the
      needle connection, leaving the 18 gauge needle in place. Then we will draw up 30cc of 0.5%
      bupivacaine with 1:200,000 epinephrine (Marcaine) with .18-gauge needle into the second 60cc
      syringe. Subsequently, we will place the filled syringe on the 18 gauge needle already in the
      knee and inject. Then we will remove the needle-syringe construct and place a bandage over
      the injection site.

      The patient's initial numerical rating scale (NRS) score will be recorded immediately.
      Subsequent visual analogue scale (VAS) scores will be recorded at 5 minutes after
      intervention and at hours 2, 4, 6, 8, 12, and 24 after initial work-up of the patient.
      Patients treated as an outpatient will record these values themselves. Patients will be
      directed to bring the completed form with them to their regular clinic follow-up visit.
      Additionally, supplemental analgesia requirements will be recorded upon administration and
      will be converted to morphine equivalent units for analysis. All patients admitted to the
      orthopedic service will be placed on patient-controlled analgesic (PCA) morphine, where the
      dose is determined by the weight of the patient. All other patients (those admitted to other
      services) will have analgesia converted to Opioid Morphine Equivalents (OMEs).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was stopped for feasibility (low enrollment)
  </why_stopped>
  <start_date type="Actual">June 15, 2016</start_date>
  <completion_date type="Actual">May 3, 2018</completion_date>
  <primary_completion_date type="Actual">May 3, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to receive aspiration of the joint alone, receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine, or receive no injection or aspiration therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>This study uses a single blind masking scheme</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical Rating Scale (NRS) Pain Scores</measure>
    <time_frame>24 hours</time_frame>
    <description>Twenty-four hours after injury, patients will self report their numerical rating scale (NRS) score. The NRS score ranges from 0 to 10 with higher scores indicating greater pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Supplemental Analgesia</measure>
    <time_frame>24 hours</time_frame>
    <description>Twenty-four hours after injury, the researchers will record the number of participants that required supplemental analgesia.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Tibial Fractures</condition>
  <arm_group>
    <arm_group_label>Aspiration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspiration with injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants assigned to this arm receive no injection or aspiration therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Aspiration</intervention_name>
    <description>A needle is placed into the knee joint and all of the blood that is in the joint is removed.</description>
    <arm_group_label>Aspiration</arm_group_label>
    <arm_group_label>Aspiration with injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>An injection of 20cc bupivacaine 0.5% with 1:200,00 epinephrine</description>
    <arm_group_label>Aspiration with injection</arm_group_label>
    <other_name>Marcaine</other_name>
    <other_name>Exparel</other_name>
    <other_name>Sensorcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with isolated tibial plateau fractures aged 18 years and older

          -  Patients with tibial plateau fractures and associated soft tissue complaints about the
             knee, not associated with a fracture outside of the tibial plateau

          -  Patients with bilateral tibial plateau fractures and no other noted fractures

        Exclusion Criteria:

          -  Any patient that does not wish to participate in the study or is unable to give
             consent at the initial encounter

          -  Patients under 18 years old

          -  Pregnant patients

          -  Patients who are unable to understand the study procedures

          -  Incarcerated patients

          -  History of allergic reaction to local anesthetics

          -  Emergent conditions requiring operations or airway protection

          -  Polytrauma patients

          -  Patients presenting for care greater than 24 hours following their injury.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Lack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Manidakis N, Dosani A, Dimitriou R, Stengel D, Matthews S, Giannoudis P. Tibial plateau fractures: functional outcome and incidence of osteoarthritis in 125 cases. Int Orthop. 2010 Apr;34(4):565-70. doi: 10.1007/s00264-009-0790-5. Epub 2009 May 14.</citation>
    <PMID>19440710</PMID>
  </reference>
  <reference>
    <citation>Koval KJ, Helfet DL. Tibial Plateau Fractures: Evaluation and Treatment. J Am Acad Orthop Surg. 1995 Mar;3(2):86-94.</citation>
    <PMID>10790657</PMID>
  </reference>
  <reference>
    <citation>Stein C, Comisel K, Haimerl E, Yassouridis A, Lehrberger K, Herz A, Peter K. Analgesic effect of intraarticular morphine after arthroscopic knee surgery. N Engl J Med. 1991 Oct 17;325(16):1123-6.</citation>
    <PMID>1653901</PMID>
  </reference>
  <reference>
    <citation>Busch CA, Shore BJ, Bhandari R, Ganapathy S, MacDonald SJ, Bourne RB, Rorabeck CH, McCalden RW. Efficacy of periarticular multimodal drug injection in total knee arthroplasty. A randomized trial. J Bone Joint Surg Am. 2006 May;88(5):959-63.</citation>
    <PMID>16651569</PMID>
  </reference>
  <reference>
    <citation>Franceschi F, Rizzello G, Cataldo R, Denaro V. Comparison of morphine and ropivacaine following knee arthroscopy. Arthroscopy. 2001 May;17(5):477-80.</citation>
    <PMID>11337713</PMID>
  </reference>
  <reference>
    <citation>Jaureguito JW, Wilcox JF, Cohn SJ, Thisted RA, Reider B. A comparison of intraarticular morphine and bupivacaine for pain control after outpatient knee arthroscopy. A prospective, randomized, double-blinded study. Am J Sports Med. 1995 May-Jun;23(3):350-3.</citation>
    <PMID>7661266</PMID>
  </reference>
  <reference>
    <citation>White BJ, Walsh M, Egol KA, Tejwani NC. Intra-articular block compared with conscious sedation for closed reduction of ankle fracture-dislocations. A prospective randomized trial. J Bone Joint Surg Am. 2008 Apr;90(4):731-4. doi: 10.2106/JBJS.G.00733.</citation>
    <PMID>18381308</PMID>
  </reference>
  <reference>
    <citation>Perdreau A, Joudet T. Efficacy of multimodal analgesia injection combined with corticosteroids after arthroscopic rotator cuff repair. Orthop Traumatol Surg Res. 2015 Dec;101(8 Suppl):S337-45. doi: 10.1016/j.otsr.2015.09.006. Epub 2015 Nov 10.</citation>
    <PMID>26563923</PMID>
  </reference>
  <reference>
    <citation>Chalidis BE, Papadopoulos PP, Sachinis NC, Dimitriou CG. Aspiration alone versus aspiration and bupivacaine injection in the treatment of undisplaced radial head fractures: a prospective randomized study. J Shoulder Elbow Surg. 2009 Sep-Oct;18(5):676-9. doi: 10.1016/j.jse.2009.04.003. Epub 2009 May 31.</citation>
    <PMID>19487135</PMID>
  </reference>
  <reference>
    <citation>Ditsios KT, Stavridis SI, Christodoulou AG. The effect of haematoma aspiration on intra-articular pressure and pain relief following Mason I radial head fractures. Injury. 2011 Apr;42(4):362-5. doi: 10.1016/j.injury.2010.09.003. Epub 2010 Oct 8.</citation>
    <PMID>20932520</PMID>
  </reference>
  <reference>
    <citation>Bijur PE, Latimer CT, Gallagher EJ. Validation of a verbally administered numerical rating scale of acute pain for use in the emergency department. Acad Emerg Med. 2003 Apr;10(4):390-2.</citation>
    <PMID>12670856</PMID>
  </reference>
  <reference>
    <citation>Heard SO, Edwards WT, Ferrari D, Hanna D, Wong PD, Liland A, Willock MM. Analgesic effect of intraarticular bupivacaine or morphine after arthroscopic knee surgery: a randomized, prospective, double-blind study. Anesth Analg. 1992 Jun;74(6):822-6.</citation>
    <PMID>1595914</PMID>
  </reference>
  <reference>
    <citation>Badner NH, Bourne RB, Rorabeck CH, MacDonald SJ, Doyle JA. Intra-articular injection of bupivacaine in knee-replacement operations. Results of use for analgesia and for preemptive blockade. J Bone Joint Surg Am. 1996 May;78(5):734-8.</citation>
    <PMID>8642030</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>October 28, 2016</study_first_submitted>
  <study_first_submitted_qc>October 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <results_first_submitted>July 19, 2018</results_first_submitted>
  <results_first_submitted_qc>August 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2018</results_first_posted>
  <last_update_submitted>August 15, 2018</last_update_submitted>
  <last_update_submitted_qc>August 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>William Lack</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Aspiration</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Epinephrine</keyword>
  <keyword>Marcaine</keyword>
  <keyword>Pain</keyword>
  <keyword>Shin Bone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma</mesh_term>
    <mesh_term>Tibial Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data (IPD) available to other researchers</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT02951884/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from June 2016 through May 2018 (24 months) from the Orthopaedic Surgery and Rehabilitation Center at Loyola University Medical Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Aspiration</title>
          <description>Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.</description>
        </group>
        <group group_id="P2">
          <title>Aspiration With Injection</title>
          <description>Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine</description>
        </group>
        <group group_id="P3">
          <title>Control</title>
          <description>Participants assigned to this arm receive no injection or aspiration therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population comprises both participants who consented to participate in the trial</population>
      <group_list>
        <group group_id="B1">
          <title>Aspiration</title>
          <description>Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.</description>
        </group>
        <group group_id="B2">
          <title>Aspiration With Injection</title>
          <description>Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>Participants assigned to this arm receive no injection or aspiration therapy.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numerical Rating Scale (NRS) Pain Scores</title>
        <description>Twenty-four hours after injury, patients will self report their numerical rating scale (NRS) score. The NRS score ranges from 0 to 10 with higher scores indicating greater pain.</description>
        <time_frame>24 hours</time_frame>
        <population>The analysis population comprises both participants who consented to participate in the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration</title>
            <description>Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.</description>
          </group>
          <group group_id="O2">
            <title>Aspiration With Injection</title>
            <description>Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Participants assigned to this arm receive no injection or aspiration therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Numerical Rating Scale (NRS) Pain Scores</title>
          <description>Twenty-four hours after injury, patients will self report their numerical rating scale (NRS) score. The NRS score ranges from 0 to 10 with higher scores indicating greater pain.</description>
          <population>The analysis population comprises both participants who consented to participate in the trial</population>
          <units>units on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Supplemental Analgesia</title>
        <description>Twenty-four hours after injury, the researchers will record the number of participants that required supplemental analgesia.</description>
        <time_frame>24 hours</time_frame>
        <population>The analysis population comprises both participants who consented to participate in the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Aspiration</title>
            <description>Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.</description>
          </group>
          <group group_id="O2">
            <title>Aspiration With Injection</title>
            <description>Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Participants assigned to this arm receive no injection or aspiration therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Supplemental Analgesia</title>
          <description>Twenty-four hours after injury, the researchers will record the number of participants that required supplemental analgesia.</description>
          <population>The analysis population comprises both participants who consented to participate in the trial</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from June 2016 through May 2018 (i.e., 24 months)</time_frame>
      <desc>Because no individuals were assigned to the aspiration group, no individuals in that group were at risk for adverse events or all cause mortality</desc>
      <group_list>
        <group group_id="E1">
          <title>Aspiration</title>
          <description>Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.</description>
        </group>
        <group group_id="E2">
          <title>Aspiration With Injection</title>
          <description>Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>Participants assigned to this arm receive no injection or aspiration therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was stopped for feasibility (low enrollment)</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>William Lack, M.D.</name_or_title>
      <organization>Loyola University Medical Center</organization>
      <phone>708-216-1175</phone>
      <email>wlack@luc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

